CSIMarket Company Name, Ticker, Customers, else..
 
Cogent Biosciences Inc   (NASDAQ: COGT)
Other Ticker:  
 
 
Price: $7.3700 $-0.20 -2.642%
Day's High: $7.7 Week Perf: -10.67 %
Day's Low: $ 7.19 30 Day Perf: -22.42 %
Volume (M): 2,031 52 Wk High: $ 12.61
Volume (M$): $ 14,965 52 Wk Avg: $8.49
Open: $7.61 52 Wk Low: $4.28



 Market Capitalization (Millions $) 812
 Shares Outstanding (Millions) 110
 Employees 93
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -242
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 1

Cogent Biosciences Inc
Cogent Biosciences Inc. is a biotechnology company that focuses on the development of precision therapies for genetically driven diseases, with a particular emphasis on oncology. The company is committed to advancing novel small molecule therapies designed to target the underlying cause of diseases. Cogent Biosciences' approach involves identifying genetic mutations and developing drugs to specifically address them, with the aim of providing patients with more effective and personalized treatment options. The company's pipeline includes potential therapies for various cancers, including gastrointestinal stromal tumors and acute myeloid leukemia. Cogent Biosciences aims to make a positive impact on patient lives by advancing innovative therapies that target the root cause of diseases.


   Company Address: 275 Wyman Street Waltham 2451 MA
   Company Phone Number: 945-5576   Stock Exchange / Ticker: NASDAQ COGT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BPMC        13.16% 
SRPT   -5.89%    
TGTX        3.37% 
VRTX   -0.11%    
XNCR   -18.44%    
ZLAB   -0.04%    
• View Complete Report
   



Management Announcement

Cogent Biosciences: Navigating Financial Turbulence While Pioneering Breakthroughs in Cancer Therapy

Published Mon, Jan 13 2025 1:02 PM UTC

As the biotech sector grapples with economic headwinds, Cogent Biosciences Inc. stands at a pivotal juncture in its mission to advance targeted therapies for cancer. Despite its cumulative net loss of $242 million over the past year, the company is forging ahead with ambitious milestones for its lead drug, Bezuclastinib, and its new portfolio of selective therapeutics. In a ...
Clinical Study

Cogent Biosciences Surpasses Enrollment Targets and Advances in GIST Phase 3 PEAK Trial Amidst Financial Challenges...

Published Tue, Sep 3 2024 12:01 PM UTC

Breaking New Ground in GIST Therapy: Cogent Biosciences Phase 3 PEAK Trial Completes Enrollment and Surpasses Interim Futility AnalysisIn a significant milestone for the fight against Gastrointestinal Stromal Tumors (GIST), Cogent Biosciences has announced that its Phase 3 PEAK trial has successfully completed enrollment and moved beyond the interim futility analysis. This...
Clinical Study

AbstractCogent Biosciences recently announced a successful meeting with the U.S. Food and Drug Admini...

Published Thu, Jun 27 2024 12:33 PM UTC

Positive FDA Meeting for Cogent Biosciences Aligns Novel MS2D2 Patient Reported Outcome Measure for SUMMIT Trial: Enrollment on Track for Completion in Q2 2025 AbstractCogent Biosciences recently announced a successful meeting with the U.S. Food and Drug Administration (FDA), revealing alignment on the implementation of a new Patient Reported Outcome (PRO) measure, MS2D2, f...
Clinical Study

Bezuclastinib Shows Promising Results in the Treatment of NonAdvanced Systemic Mastocytosis

Published Fri, Jun 14 2024 11:30 AM UTC

In their recent announcement, Cogent Biosciences revealed additional clinical data from Part 1 of the SUMMIT trial, showcasing the potential of bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM). The trial evaluated the efficacy and safety of this promising drug, and the results have generated significant excitement within the medical community.Key F...
Clinical Study

Promising Updated Lead-In Data from the PEAK Trial: Bezuclastinib Combination Therapy Shows Potential for Gastrointestinal Stromal Tumors

Published Thu, May 23 2024 9:01 PM UTC

In recent news, Cogent Biosciences, Inc. has shared positive updated lead-in data from their ongoing Phase 3 PEAK trial. The trial assesses the efficacy of bezuclastinib, a selective and potent KIT mutant inhibitor, in combination with sunitinib for the treatment of Gastrointestinal Stromal Tumors (GIST). These findings were presented in a poster at the American Society of C...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com